OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2025
(2)
2017
(2)
2023
(1)
2022
(1)
2019
(1)
2018
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition.
Not available
S-EPMC5497352
|
biostudies-literature
Cite
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.
Not available
S-EPMC5711884
|
biostudies-literature
Cite
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Not available
S-EPMC6517433
|
biostudies-literature
Cite
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Not available
S-EPMC6137048
|
biostudies-literature
Cite
Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery.
Not available
S-EPMC10163929
|
biostudies-literature
Cite
Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening.
Not available
S-EPMC9669819
|
biostudies-literature
Cite
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861
|
biostudies-literature
Cite
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Not available
S-EPMC11869088
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets